- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Ascending Aorta.
Displaying page 1 of 2.
EudraCT Number: 2013-002820-18 | Sponsor Protocol Number: NL45370.020.13 | Start Date*: 2014-07-11 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Comparison of a single dose fibrinogen with placebo and the number of blood transfusions after ascending aorta surgery (FIBTEG study) | ||
Medical condition: Patients who need thoracic aortic reconstruction surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000513-14 | Sponsor Protocol Number: NBK154/2/2021 | Start Date*: 2023-03-08 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-b... | ||
Medical condition: Marfan Syndrome Diseases related to Marfan syndrome (rare diseases with aneurysms of the thoracic aorta and dissection of the aorta), among others: Loeys-Dietz syndrome, Vascular type of Ehlers-Da... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018880-41 | Sponsor Protocol Number: CARDPED-2010-01 | Start Date*: 2010-06-01 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: EFFECTS OF LOSARTAN ON AORTIC ROOT AND ASCENDING AORTA REMODELING IN PATIENTS WITH BICUSPID AORTIC VALVE. | |||||||||||||
Medical condition: PATIENTS WITH BICUSPID AORTIC VALVE. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000538-12 | Sponsor Protocol Number: HLK-VASC-11/01 | Start Date*: 2011-06-14 |
Sponsor Name:VU University Medical Center | ||
Full Title: An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients wit... | ||
Medical condition: Abdominal Aortic Aneurysm Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000028-15 | Sponsor Protocol Number: TC-023-IM | Start Date*: 2007-01-26 |
Sponsor Name:Nycomed Danmark ApS | ||
Full Title: A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in the cardiovascular surgery | ||
Medical condition: Supportive haemostatic treatment in patients having elective surgery on the heart, the ascending aorta or arch, requiring pulmonary bypass procedure. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) DK (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001808-57 | Sponsor Protocol Number: BICATOR | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Assessment of atorvastatin efficacy on the progression of aortic dilatation and valvular degeneration in patients with bicuspid aortic valve (BICATOR) | |||||||||||||
Medical condition: Valve Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003697-14 | Sponsor Protocol Number: PsoPET2 | Start Date*: 2017-12-18 | |||||||||||||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-sever... | |||||||||||||||||||||||
Medical condition: Moderate-to-severe psoriasis. Vascular and systemic (splenic) inflammation in psoriasis subjects. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023612-14 | Sponsor Protocol Number: N/A | Start Date*: 2013-03-08 | |||||||||||
Sponsor Name:Clinical Trials and Research Governance | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic reso... | |||||||||||||
Medical condition: Marfan syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004078-53 | Sponsor Protocol Number: 83403 | Start Date*: 2023-08-22 |
Sponsor Name:Academic Medical Center (AMC), department of Internal Medicine | ||
Full Title: Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping | ||
Medical condition: - Plaque characteristics - Systemic inflammation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003942-33 | Sponsor Protocol Number: M13-796 | Start Date*: 2013-05-03 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk... | |||||||||||||
Medical condition: Acute Kidney Injury | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002541-11 | Sponsor Protocol Number: P170912J | Start Date*: 2019-06-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery | |||||||||||||
Medical condition: Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003164-62 | Sponsor Protocol Number: 1976 | Start Date*: 2007-01-22 |
Sponsor Name:University Hospital Birmingham | ||
Full Title: Metabolic Support with Perhexilene to Protect Myocardium undergoing Coronary Artery Surgery | ||
Medical condition: Patients undergoing coronary artery bypass surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002376-95 | Sponsor Protocol Number: RRK3535 | Start Date*: 2009-01-05 |
Sponsor Name:University Hospital Birmingham NHS Foundation Trust | ||
Full Title: Myocardial protection with Perhexiline in Left Ventricular Hypertrophy | ||
Medical condition: Patients with left ventricular hypertrophy undergoing aortic valve surgery (with or without coronary artery surgery) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005130-27 | Sponsor Protocol Number: IVORY | Start Date*: 2019-11-08 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||
Full Title: Low-dose interleukin-2 for the reduction of vascular inflammation in Acute Coronary Syndromes (IVORY) | |||||||||||||
Medical condition: Acute Coronary Syndrome (ACS) such as myocardial infarction and unstable angina | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022630-92 | Sponsor Protocol Number: AP214-CS007 | Start Date*: 2010-11-05 | |||||||||||
Sponsor Name:Action Pharma A/S | |||||||||||||
Full Title: An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Su... | |||||||||||||
Medical condition: Action Pharma is developing AP214 Acetate for the prevention of postsurgical kidney injury after cardiac surgery. Trial population is patients with increased risk for development of Kidney Inju... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002752-20 | Sponsor Protocol Number: LAN_POAF_01 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: A prospective, randomized, double- blind, placebo- controlled study to evaluate the efficacy of Landiolol hydrochloride for prevention of atrial fibrillation in patients undergoing cardiac surgery | |||||||||||||
Medical condition: Perioperative atrial fibrillation (POAF) is the most common arryhthmia after cardiac surgery with incidences ranging from 20% to 40%, depending on various patient's risk factors and the type of sur... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003464-31 | Sponsor Protocol Number: BIOS-13-004 | Start Date*: 2014-02-21 |
Sponsor Name:Ethicon Inc | ||
Full Title: A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Sur... | ||
Medical condition: subjects undergoing major aortic surgery, including ascending, arch, or descending aorta replacement, requiring adjunctive support for hemostasis at the anastomotic suture line | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004040-19 | Sponsor Protocol Number: 21-ROS-05 | Start Date*: 2022-02-09 | |||||||||||
Sponsor Name:Guard Therapeutics International AB | |||||||||||||
Full Title: A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Foll... | |||||||||||||
Medical condition: Cardiac surgery associated acute kidney injury | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002556-27 | Sponsor Protocol Number: ALBICS | Start Date*: 2016-11-25 | |||||||||||
Sponsor Name:Helsinki University Hospital | |||||||||||||
Full Title: Albumin in cardiac surgery | |||||||||||||
Medical condition: Cardiac surgery with cardiopulmonary bypass operations. Elective and emergency patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003113-15 | Sponsor Protocol Number: QRK209 | Start Date*: 2016-08-02 | |||||||||||
Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI following Ca... | |||||||||||||
Medical condition: QPI-1002 is being developed for prevention of acute kidney injury (AKI) in patients at risk for AKI following cardiac surgery and for reduction in the incidence and severity of delayed graft functi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.